Cardiff Oncology, Inc. (CRDF): Operating Cash Flow
-$37.92M
Year ended 2025-12-31
-$40.85M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$37.92M | n/m | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | -$37.69M | n/m | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | -$30.89M | n/m | 2025-02-27, From 2023-01-01 |
| 2022-12-31 | -$33.82M | n/m | 2024-02-29, From 2022-01-01 |
| 2021-12-31 | -$23.04M | n/m | 2023-03-02, From 2021-01-01 |
| 2020-12-31 | -$16.32M | n/m | 2022-02-24, From 2020-01-01 |
| 2019-12-31 | -$13.27M | n/m | 2021-02-25, From 2019-01-01 |
| 2018-12-31 | -$13.20M | n/m | 2020-02-27, From 2018-01-01 |
| 2017-12-31 | -$23.28M | n/m | 2019-03-06, From 2017-01-01 |
| 2016-12-31 | -$31.04M | n/m | 2018-02-26, From 2016-01-01 |
| 2015-12-31 | -$22.12M | n/m | 2017-03-15, From 2015-01-01 |
| 2014-12-31 | -$12.73M | n/m | 2017-03-15, From 2014-01-01 |
| 2013-12-31 | -$7.32M | n/m | 2016-03-10, From 2013-01-01 |
| 2012-12-31 | -$4.93M | n/m | 2015-03-12, From 2012-01-01 |
| 2011-12-31 | -$1.93M | n/a | 2014-03-17, From 2011-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | -$37.92M | n/m |
| ImageneBio, Inc. (IMA) | 2025-12-31 | -$47.84M | n/m |
| Prokidney Corp. (PROK) | 2025-12-31 | -$120.12M | n/m |
| Pluri Inc. (PLUR) | 2026-06-30 | -$19.59M | n/m |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | -$129.79M | n/m |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | -$6.03M | n/m |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | -$51.83M | n/m |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | -$61.99M | n/m |
| Humacyte, Inc. (HUMA) | 2025-12-31 | -$105.04M | n/m |
Compare CRDF, IMA, PROK, PLUR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗